Vergoeding 2016-2020 voor ATC-subgroep A10AE : Langwerkende insulines voor injectie
- Raming voor de totale Zvw-populatie
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| A10AE04 Insuline glargine (Lantus ®) | 50.254.700 | 46.567.900 | 43.865.300 | 41.090.800 | 38.621.200 |
| A10AE05 Insuline detemir (Levemir ®) | 17.953.000 | 14.744.500 | 12.206.400 | 10.386.300 | 8.845.000 |
| A10AE06 Insuline degludec (Tresiba ®) | 7.185.200 | 13.313.200 | 18.504.900 | 19.258.600 | 19.143.100 |
| A10AE54 Insuline glargine met lixisenatide (Suliqua ®) | . | 85.617 | 428.860 | 656.690 | 444.440 |
| A10AE56 Insuline degludec met liraglutide (Xultophy ®) | . | 1.570.500 | 3.567.700 | 3.518.400 | 2.805.100 |
| Totaal | 75.392.900 | 76.281.717 | 78.573.160 | 74.910.790 | 69.858.840 |